RS56135B1 - Kompozicije i metode za lečenje plućne hipertenzije - Google Patents
Kompozicije i metode za lečenje plućne hipertenzijeInfo
- Publication number
- RS56135B1 RS56135B1 RS20170640A RSP20170640A RS56135B1 RS 56135 B1 RS56135 B1 RS 56135B1 RS 20170640 A RS20170640 A RS 20170640A RS P20170640 A RSP20170640 A RS P20170640A RS 56135 B1 RS56135 B1 RS 56135B1
- Authority
- RS
- Serbia
- Prior art keywords
- compositions
- methods
- pulmonary hypertension
- treating pulmonary
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39352910P | 2010-10-15 | 2010-10-15 | |
| US201161490454P | 2011-05-26 | 2011-05-26 | |
| US201161497475P | 2011-06-15 | 2011-06-15 | |
| PCT/US2011/056404 WO2012051559A2 (en) | 2010-10-15 | 2011-10-14 | Compositions and methods of treating pulmonary hypertension |
| EP11833507.4A EP2637664B1 (en) | 2010-10-15 | 2011-10-14 | Compositions and methods of treating pulmonary hypertension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS56135B1 true RS56135B1 (sr) | 2017-10-31 |
Family
ID=45939010
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20170640A RS56135B1 (sr) | 2010-10-15 | 2011-10-14 | Kompozicije i metode za lečenje plućne hipertenzije |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US20120269898A1 (sr) |
| EP (2) | EP3106163A1 (sr) |
| JP (2) | JP5806320B2 (sr) |
| KR (2) | KR20150002876A (sr) |
| CN (1) | CN103458690B (sr) |
| AR (1) | AR083422A1 (sr) |
| AU (2) | AU2011315891B2 (sr) |
| BR (1) | BR112013008983A2 (sr) |
| CA (1) | CA2814518C (sr) |
| CY (1) | CY1119007T1 (sr) |
| DK (1) | DK2637664T3 (sr) |
| EA (2) | EA026074B1 (sr) |
| ES (1) | ES2627944T3 (sr) |
| HR (1) | HRP20170848T1 (sr) |
| HU (1) | HUE033346T2 (sr) |
| LT (1) | LT2637664T (sr) |
| MX (1) | MX346730B (sr) |
| NZ (2) | NZ707213A (sr) |
| PL (1) | PL2637664T3 (sr) |
| PT (1) | PT2637664T (sr) |
| RS (1) | RS56135B1 (sr) |
| SI (1) | SI2637664T1 (sr) |
| TW (1) | TWI542580B (sr) |
| WO (1) | WO2012051559A2 (sr) |
| ZA (1) | ZA201302746B (sr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2101777E (pt) | 2006-12-12 | 2015-09-18 | Gilead Sciences Inc | Composição para tratar uma hipertensão pulmonar |
| AU2011315891B2 (en) | 2010-10-15 | 2015-08-13 | Gilead Sciences, Inc. | Compositions and methods of treating pulmonary hypertension |
| WO2014003678A1 (en) * | 2012-06-28 | 2014-01-03 | Xspray Microparticles Ab | Pharmaceutical compositions comprising ambrisentan and solid dispersion particles containing tadalafil |
| WO2014174529A2 (en) * | 2013-04-23 | 2014-10-30 | Hetero Research Foundation | Polymorphs of avanafil |
| WO2015069839A1 (en) * | 2013-11-06 | 2015-05-14 | Gilead Sciences, Inc. | Combination therapy for treating pulmonary hypertension |
| CN105581990A (zh) * | 2014-08-27 | 2016-05-18 | 人福医药集团股份公司 | 安立生坦片剂及其制备方法 |
| US10456404B2 (en) | 2015-03-13 | 2019-10-29 | Indiana University Research And Technology Corporation | Targeting cGMP-related phosphodiesterases to reduce cyst formation in cystic kidney disease, and related materials and methods |
| PT3496739T (pt) * | 2016-07-15 | 2021-06-21 | Acceleron Pharma Inc | Composições compreendendo polipéptidos actriia para uso no tratamento de hipertensão pulmonar |
| WO2018081567A1 (en) * | 2016-10-27 | 2018-05-03 | Pulmokine, Inc. | Combination therapy for treating pulmonary hypertension |
| US20200215065A1 (en) * | 2017-07-07 | 2020-07-09 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and method for treating pulmonary hypertension |
| CN111683683A (zh) | 2017-12-26 | 2020-09-18 | Ftf药业私人有限公司 | Pde v抑制剂的液体口服制剂 |
| CN109406688A (zh) * | 2018-09-28 | 2019-03-01 | 中国食品药品检定研究院 | 用于检测产品中违禁药品的标准样品 |
| MX2022006403A (es) * | 2019-11-29 | 2022-08-25 | Actelion Pharmaceuticals Ltd | Metodos de tratamiento de hipertension de la arteria pulmonar. |
| CA3161960A1 (en) | 2019-12-16 | 2021-06-24 | Tenax Therapeutics, Inc. | Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (ph-hfpef) |
| KR102606504B1 (ko) * | 2020-04-10 | 2023-11-29 | 주식회사 대웅테라퓨틱스 | 니클로사마이드를 포함하는 폐고혈압의 예방 및 치료용 조성물 |
| CN112826944B (zh) * | 2021-01-29 | 2023-08-15 | 台州职业技术学院 | 一种安立生坦包合物及其制备方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| US5250534A (en) | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
| DE4313412A1 (de) | 1993-04-23 | 1994-10-27 | Basf Ag | 3-(Het)aryl-Carbonsäurederivate, Verfahren und Zwischenprodukte zu ihrer Herstellung |
| GB9401090D0 (en) | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
| DE19533023B4 (de) | 1994-10-14 | 2007-05-16 | Basf Ag | Neue Carbonsäurederivate, ihre Herstellung und Verwendung |
| DE59803108D1 (de) | 1997-11-12 | 2002-03-21 | Bayer Ag | 2-phenyl-substituierte imidazotriazinone als phosphodiesterase inhibitoren |
| US6821975B1 (en) | 1999-08-03 | 2004-11-23 | Lilly Icos Llc | Beta-carboline drug products |
| EP1776108A1 (en) | 2004-06-23 | 2007-04-25 | Myogen, Inc. | Enoximone formulations and their use in the treatment of pde-iii mediated diseases |
| CN101072564A (zh) * | 2004-08-26 | 2007-11-14 | 恩希赛弗制药公司 | 内皮缩血管肽a受体(eta)拮抗剂与磷酸二酯酶5(pde5)抑制剂的联合及其用途 |
| US20060205733A1 (en) * | 2004-08-26 | 2006-09-14 | Encysive Pharmaceuticals | Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof |
| MEP23808A (en) | 2006-04-21 | 2010-06-10 | Pfizer Prod Inc | Pyridine[3,4-b]pyrazinones |
| PT2101777E (pt) * | 2006-12-12 | 2015-09-18 | Gilead Sciences Inc | Composição para tratar uma hipertensão pulmonar |
| EP2091539A1 (en) * | 2006-12-12 | 2009-08-26 | Gilead Colorado, Inc. | Ambrisentan combined with a renin inhibitor for hypertensive disorder |
| MX2010001255A (es) | 2007-07-31 | 2010-12-06 | Gilead Colorado Inc | Metabolitos y derivados de ambrisentan. |
| WO2010062640A1 (en) | 2008-10-28 | 2010-06-03 | Gilead Colorado, Inc. | Methods for treating idiopathic pulmonary fibrosis and associated complications |
| AU2011315891B2 (en) | 2010-10-15 | 2015-08-13 | Gilead Sciences, Inc. | Compositions and methods of treating pulmonary hypertension |
-
2011
- 2011-10-14 AU AU2011315891A patent/AU2011315891B2/en active Active
- 2011-10-14 NZ NZ707213A patent/NZ707213A/en active IP Right Revival
- 2011-10-14 CN CN201180060879.3A patent/CN103458690B/zh not_active Expired - Fee Related
- 2011-10-14 TW TW100137481A patent/TWI542580B/zh not_active IP Right Cessation
- 2011-10-14 PL PL11833507T patent/PL2637664T3/pl unknown
- 2011-10-14 PT PT118335074T patent/PT2637664T/pt unknown
- 2011-10-14 DK DK11833507.4T patent/DK2637664T3/en active
- 2011-10-14 US US13/274,013 patent/US20120269898A1/en not_active Abandoned
- 2011-10-14 CA CA2814518A patent/CA2814518C/en not_active Expired - Fee Related
- 2011-10-14 BR BR112013008983A patent/BR112013008983A2/pt not_active IP Right Cessation
- 2011-10-14 EA EA201390428A patent/EA026074B1/ru active IP Right Revival
- 2011-10-14 KR KR20147032816A patent/KR20150002876A/ko not_active Application Discontinuation
- 2011-10-14 NZ NZ610012A patent/NZ610012A/en active IP Right Revival
- 2011-10-14 RS RS20170640A patent/RS56135B1/sr unknown
- 2011-10-14 WO PCT/US2011/056404 patent/WO2012051559A2/en active Application Filing
- 2011-10-14 JP JP2013534043A patent/JP5806320B2/ja not_active Expired - Fee Related
- 2011-10-14 MX MX2013004190A patent/MX346730B/es active IP Right Grant
- 2011-10-14 KR KR1020137012382A patent/KR20130069855A/ko active Search and Examination
- 2011-10-14 ES ES11833507.4T patent/ES2627944T3/es active Active
- 2011-10-14 HU HUE11833507A patent/HUE033346T2/en unknown
- 2011-10-14 LT LTEP11833507.4T patent/LT2637664T/lt unknown
- 2011-10-14 EA EA201691759A patent/EA201691759A1/ru unknown
- 2011-10-14 EP EP16180914.0A patent/EP3106163A1/en not_active Withdrawn
- 2011-10-14 SI SI201131190A patent/SI2637664T1/sl unknown
- 2011-10-14 EP EP11833507.4A patent/EP2637664B1/en not_active Revoked
- 2011-10-17 AR ARP110103833A patent/AR083422A1/es unknown
-
2013
- 2013-04-17 ZA ZA2013/02746A patent/ZA201302746B/en unknown
- 2013-11-13 US US14/079,548 patent/US9549926B2/en active Active
-
2015
- 2015-06-10 JP JP2015117196A patent/JP2015178528A/ja not_active Withdrawn
-
2016
- 2016-07-04 AU AU2016204638A patent/AU2016204638B2/en not_active Ceased
- 2016-08-09 US US15/232,570 patent/US20160346280A1/en not_active Abandoned
-
2017
- 2017-06-05 HR HRP20170848TT patent/HRP20170848T1/hr unknown
- 2017-06-22 CY CY20171100660T patent/CY1119007T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201302746B (en) | Compositions and methods of treating pulmonary hypertension | |
| IL250824B (en) | Certain amino-pyrimidines, their assemblies, and methods of using them | |
| EP2536756A4 (en) | HSA-RELATED COMPOSITIONS AND USE PROCESSES | |
| EP2584897A4 (en) | COMPOSITIONS CONTAINING RESVERATROL AND METHODS OF USE | |
| EP2603202A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF TAUOPATHIES | |
| HK1203049A1 (en) | Intranasal dexmedetomidine compositions and methods of use thereof | |
| EP2534205A4 (en) | RHEOLOGY MODIFIER COMPOSITIONS AND METHODS OF USE | |
| EP2603199A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | |
| EP2542060A4 (en) | COMPOSITIONS AND METHODS FOR TREATMENT AND / OR PREVENTION OF CARDIOVASCULAR DISEASES | |
| EP2675471A4 (en) | HSA-RELATED COMPOSITIONS AND USE PROCESSES | |
| EP2596112A4 (en) | ACETYCYSTEIN COMPOSITIONS AND USE METHOD THEREFOR | |
| IL222291A0 (en) | Compositions and methods of synthesis of pyridinoylpiperidine | |
| EP2593571A4 (en) | SWEETENER COMPOSITIONS AND METHODS OF PRODUCING THE SAME | |
| EP2576579A4 (en) | COMPOSITIONS AND METHODS FOR TREATING HEPATIC FIBROSIS | |
| WO2011137427A9 (en) | Compositions and methods for treating pulmonary conditions | |
| EP2622029A4 (en) | PRINTING COLORING COMPOSITIONS AND METHOD FOR THEIR USE | |
| HK1189501A1 (zh) | 抗體組合物及使用方法 | |
| HK1258467A1 (zh) | 用於預防和治療心臟肥大的方法和組合物 | |
| EP2755668A4 (en) | COMPOSITIONS OF HYR1 AND TREATMENT PROCEDURES THEREWITH | |
| EP2566485A4 (en) | IMMUNOSTIMULATORY COMPOSITIONS AND METHODS OF USE THEREOF | |
| GB201018650D0 (en) | Methods and compositions | |
| EP2643015A4 (en) | COMPOSITIONS AND METHODS | |
| HK1166953A1 (en) | Compositions and methods of use | |
| EP2563923A4 (en) | COMPOSITIONS AND METHODS FOR REDUCING SCARS AND TREATING FIBROSIS | |
| WO2011130605A9 (en) | Compositions and methods for treating pulmonary hypertension |